Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: Acad - You Need To See This

ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business develo

MarketBeat

ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according to comments at the Bank of America Global Healthcare Conference. Chief Executive Officer Cat

MarketBeat

This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) released topline results on Wednesday from its Phase 3 COMPASS PWS trial evaluating the efficacy and safety of intranasal carbetocin (ACP-101) in patients with hyperphagia in Prader-Willi syndrome (PWS).

Benzinga

3 Hidden Bargains in the Healthcare Sector

Healthcare’s resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally sound stocks like Viatris (VTRS), Bausch + Lomb Corp. (BLCO), and ACADIA Pharmaceuticals (ACAD). With strong industry tailwinds and discounted valuations, these stocks could offer…

StockNews.com

3 Specialty Pharma Stocks Addressing Unmet Medical Needs

The specialty pharma sector is leading the charge in developing life-changing solutions for rare and chronic conditions. Amid this backdrop, investors might consider adding three fundamentally solid specialty pharma stocks, namely, Ipsen S.A. (IPSEY), ACADIA Pharmaceuticals (ACAD), and Neurocrine Biosciences (NBIX) in their portfolios. Read on….

StockNews.com

3 Healthcare Stocks Analysts Expect to Rally Over 50%

With the growing demand for innovative healthcare services, increasing spending, and rising tech adoption, the healthcare market is booming. Amid this backdrop, investors could check out quality healthcare stocks ACADIA Pharmaceuticals (ACAD), Harvard Bioscience (HBIO), and LAVA Therapeutics (LVTX), which have significant upside potential. Continue reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Mid-Cap Stocks Analysts Believe Will Soar 50% or More

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

StockNews.com

3 Pharma Stocks to Buy for Potential Financial Fortunes

Amid surging medicine demand and ongoing drug shortages, the pharmaceutical industry thrives, driving improved patient outcomes and promising growth opportunities for investors. So, it could be wise to invest in quality pharma stocks ACADIA Pharmaceuticals (ACAD), Neurocrine Biosciences (NBIX), and Supernus Pharmaceuticals (SUPN), which can help you fetch potential financial…

StockNews.com

Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now

With rising medicine demand and drug shortages in the U.S., pharmaceutical stocks under $20 present lucrative opportunities for investors, promising substantial returns in a ripe market. So, I think fundamentally solid pharma stocks ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), and OptiNose (OPTN), which are currently trading under $20, could be…

StockNews.com

3 Affordable Pharma Stocks to Buy for Portfolio Gains

The pharmaceutical market is anticipated to grow substantially in the upcoming years, owing to technological innovation and rising demand for personalized medicines. To that end, affordable pharma stocks ACADIA Pharmaceuticals (ACAD), Astellas Pharma (ALPMY), and Spero Therapeutics (SPRO), trading under $20, could be solid buys now. Read on….

StockNews.com

4 Cutting-Edge Pharma Stocks for Portfolio Diversification

The pharmaceutical industry is expected to grow rapidly due to increasing healthcare demand, technological advancements, and rising demand for innovative drugs. Therefore, for portfolio diversification, investors could consider buying fundamentally strong pharmaceutical stocks such as Bayer (BAYRY), Procaps Group (PROC), ACADIA Pharmaceuticals (ACAD), and Zoetis (ZTS). Read more.

StockNews.com

Bolster Your Portfolio with These 3 Pharma Stock Buys

The pharmaceutical industry is booming because of the increasing need for quality healthcare and high-quality medicines, the fast-growing elderly population, and the uptick in chronic illnesses. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Perrigo Company (PRGO), ACADIA Pharmaceuticals (ACAD), and Pacira BioSciences…

StockNews.com

3 Pharma Stocks to Buy for February Gains

The pharmaceutical industry is thriving due to the growing demand for quality healthcare and high-quality drugs, a rapidly aging population, and the rise in chronic diseases. To capitalize on the industry’s growth prospects, investors could consider buying fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Bausch Health Companies (BHC), and ACADIA…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Stocks Building up Major Momentum

Despite lingering macroeconomic headwinds, the broader market has shown remarkable fortitude this year and is poised for an even greater surge ahead. Hence, it could be wise to invest in fundamentally sound stocks Assurant (AIZ), ACADIA Pharmaceuticals (ACAD), and Accel Entertainment (ACEL), which have gained significant momentum lately. Continue reading….

Benzinga

Analysts Try To See Beyond Acadia's Alzheimer's Disease Psychosis

HC Wainwright says that a negative AdCom vote on Acadia Pharmaceuticals Inc&#

Benzinga

HC Wainwright Sees Opportunity For Acadia's Alzheimer's Candidate

HC Wainwright says FDA's briefing document on ACADIA Pharmaceuticals Inc's (NASDAQ: ACAD) pimavanserin was not unexpected.

Benzinga

Why ACADIA Pharmaceuticals Shares Are Trading Higher Today?

Ahead of Acadia Pharmaceuticals Inc's (NASDAQ:ACAD) FDA AdComm meeting on Friday, the agency officials released their briefing documents, revealing a mixed bag of opinions. The company's resubmitted supplemental New Drug Application for pimavanserin for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP) has a target action date of August 4. Initially, the FDA…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

ACADIA Pharmaceuticals: Q1 Earnings Insights

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga

ACADIA Pharmaceuticals's Earnings Outlook

ACADIA Pharmaceuticals (NASDAQ:ACAD) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that ACADIA Pharmaceuticals will report an earnings per share (EPS) of $-0.60.

Benzinga

Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves toes back into the correct position. RBC Capital Markets writes that although trends of pain reduction were observed in the 400 mg QID ACP-044 arm compared…

Benzinga

What 7 Analyst Ratings Have To Say About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals (NASDAQ:ACAD) has observed the following analyst ratings within the last quarter:

Benzinga

Why Acadia Pharma Shares Are Falling Today

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.

Benzinga

Expert Ratings For ACADIA Pharmaceuticals

Over the past 3 months, 18 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ:ACAD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Recap: ACADIA Pharmaceuticals Q4 Earnings

ACADIA Pharmaceuticals (NASDAQ:ACAD) reported its Q4 earnings results on Monday, February 28, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.